519 related articles for article (PubMed ID: 21215675)
1. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
Li B; Zhang Y; Yuan Y; Chen N
Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
[TBL] [Abstract][Full Text] [Related]
2. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
3. alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.
Xilouri M; Vogiatzi T; Vekrellis K; Stefanis L
Autophagy; 2008 Oct; 4(7):917-9. PubMed ID: 18708765
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Spiro AS; Furuta A; Cooper A; Garner B; Kabuta T; Halliday GM
Mov Disord; 2015 Oct; 30(12):1639-47. PubMed ID: 25594542
[TBL] [Abstract][Full Text] [Related]
6. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease.
Pan T; Kondo S; Le W; Jankovic J
Brain; 2008 Aug; 131(Pt 8):1969-78. PubMed ID: 18187492
[TBL] [Abstract][Full Text] [Related]
7. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
Prigione A; Piazza F; Brighina L; Begni B; Galbussera A; Difrancesco JC; Andreoni S; Piolti R; Ferrarese C
Neurosci Lett; 2010 Jun; 477(1):6-10. PubMed ID: 20399833
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
[TBL] [Abstract][Full Text] [Related]
10. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
12. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
13. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Xilouri M; Brekk OR; Landeck N; Pitychoutis PM; Papasilekas T; Papadopoulou-Daifoti Z; Kirik D; Stefanis L
Brain; 2013 Jul; 136(Pt 7):2130-46. PubMed ID: 23757764
[TBL] [Abstract][Full Text] [Related]
14. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
15. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
Halliday GM; McCann H
Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
[TBL] [Abstract][Full Text] [Related]
16. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
17. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
20. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
